Trial pipeline accelerates: 21,411 active studies worldwide
The global translational pipeline is still compounding: ClinicalTrials.gov lists 21,411 active gene, cell, mRNA, and SI trials, while the last 24 hours added 34 new Wire signals and 21 new Cure research signals. Recent Cure items cluster around “make it usable” progress—from WHO target product profiles for dengue therapeutics (tightening ethics, regulatory, and implementation pathways) to perioperative ivonescimab in resectable non-small cell lung cancer (new phase 2 evidence reported in Nature Medicine). On the tools side, AI-informed methods keep moving from prototypes toward decision criteria and benchmarking, including AI-guided cryo-EM re-refinement selection and SPaRTA for spatial reasoning in text-to-SQL over omics. The stakes remain straightforward: faster, better-structured evidence and deployable AI workflows let more therapies reach patients with fewer wasted cycles—especially in infectious disease and high-burden cancers. The window is still open.
ClinicalTrials.gov reports 21,411 active gene, cell, mRNA and SI trials worldwide.
More active trials plus new Cure signals increases the odds that effective interventions—especially for dengue and cancer—move from research into ethically and implementably scalable treatments.
Watch for implementation-grade outputs like WHO target product profiles and perioperative regimen updates, and pressure your teams to convert new Cure/tool signals into testable next steps immediately.